Drug Trial Radar · NCT04926818
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
129
Actual
Start
Oct 5, 2021
Primary completion
Mar 25, 2026
Study completion Feb 28, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Conditions
- Multiple Sclerosis (MS)
Interventions
FingolimodDrug
Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
OfatumumabDrug
Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
SiponimodDrug
Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
Fingolimod placeboOther
Fingolimod matching placebo capsule
Siponimod placeboOther
Siponimod matching placebo tablet
Ofatumumab placeboOther
Ofatumumab matching placebo autoinjector
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rate (ARR) in target pediatric participantsTime frame: Baseline up to 24 months
Locations
51 sites in 25 countries. Site status is shown where the registry gives one.
Arkansas Childrens Hosp Rsch Inst
Little Rock, Arkansas
Childrens Hospital Los Angeles
Los Angeles, California
Childrens National Medical Center
Washington D.C., District of Columbia
Axiom Clinical Research of Florida
Tampa, Florida
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
Medical College of Wisconsin
Milwaukee, Wisconsin
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Esneux, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Lo Barnechea, Santiago Metropolitan, Chile
Novartis Investigative Site
Zagreb, Croatia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Guatemala City, Guatemala
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Riga, Latvia
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Gdansk, Poland
Novartis Investigative Site
Lodz, Poland
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Coimbra, Portugal
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.